China Medicine Corporation (CHME) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of China Medicine Corporation $0.04, price $0.03, upside +21.6%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch China Medicine Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0001 – $0.0675 · fair‑value band $0.0324 – $0.0472 · the $0.0310 price screens below the $0.0377 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow China Medicine in your weekly email
Every Wednesday you see whether China Medicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds.
Show more
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.
Stock analysis
China Medicine Corporation (CHME) currently trades at $0.0310, while our model-based Fair Value estimate is $0.0377, implying the stock looks roughly 17.8% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0431 per share, and 5 of the 10 models we run sit above the $0.0310 price.
Bear case: the Asset-Based group reads lowest at $0.0043, and 5 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0324 (bear) to $0.0472 (bull), the price of $0.0310 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
China Medicine Corporation reported revenue of $64.8M in FY2009 versus $10.4M in FY2004, a compound +44.2%/yr. Reported net income was −$7.5K in FY2025.
Key figures
Market cap $946K · EPS (TTM) $−0.0100 · Net margin 9.2% · Return on equity 6.6% · Return on assets (EBIT) 27.7% · Operating margin 14.2% · Revenue (TTM) $65.8M · Revenue growth (YoY) −8.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 2,483% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 22%, CHME screens richer than that median.
Fair Value models
Bear $0.0324Fair Value $0.0377Bull $0.0472
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.2%
’04
’06
’07
’08
’09
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
23.2% (2004) → 18.9% (2009)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare China Medicine Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+22% · Above median
Profitability
Return on equity (TTM)7% · Below median
Return on assets8% · Top 25%
Net margin (TTM)9% · Top 25%
Operating margin (TTM)14% · Top 25%
Growth and dividend
Revenue growth−8% · Bottom 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "China Medicine Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CHME
Frequently asked questions
Is China Medicine Corporation (CHME) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0377 versus a price of $0.0310, about +22% upside (undervalued).
What is the fair value of CHME?
Our model-based fair value for China Medicine Corporation is $0.0377 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0310.
What is the quality score of CHME?
China Medicine Corporation has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Medicine Corporation (CHME)?
Our model-based price target is the fair value of $0.0377 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $0.0324, optimistic scenario $0.0472. It is a calculation from audited fundamentals, not an analyst target.
What is the China Medicine Corporation stock forecast for 2026?
Our models put fair value at $0.0377, about +22% upside versus a price of $0.0310 (undervalued). Cautious scenario $0.0324, optimistic scenario $0.0472. The calculation is refreshed regularly with new filings.
What is the revenue of China Medicine Corporation (CHME)?
China Medicine Corporation reported trailing-twelve-month revenue of about $65.8M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of China Medicine Corporation (CHME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Medicine Corporation it is $0.0377 per share (as of Sep 24, 2026), against a price of $0.0310. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is China Medicine Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CHME trades below its calculated fair value: price $0.0310, fair value $0.0377, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHME?
No. The price is what the market pays today ($0.0310); the fair value is what the company's own numbers justify ($0.0377). For China Medicine Corporation the two are $0.0067 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Medicine Corporation worth?
The market values China Medicine Corporation at about $946K (market capitalisation, as of Sep 24, 2026). Per share that is $0.0310; our models calculate a fair value of $0.0377 per share.
What do the bullish and bearish scenarios say about CHME?
Our models span a range for China Medicine Corporation: cautious scenario $0.0324, base $0.0377, optimistic $0.0472 per share (as of Sep 24, 2026, price $0.0310). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of China Medicine Corporation (CHME)?
Balance-sheet figures for China Medicine Corporation (as of Sep 24, 2026): return on equity 6.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is CHME from its 52-week high?
China Medicine Corporation trades at $0.0310, about 54% below its 52-week high of $0.0675 and 2,483% above the low of $0.0012 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0377 is for.
Which stocks are comparable to China Medicine Corporation?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Medicine Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0310, calculated fair value $0.0377 (+22%), Quality Score 46/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHME calculated?
We run China Medicine Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0377, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. China Medicine Corporation currently trades 22 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Medicine Corporation (CHME)?
The closing price on Sep 24, 2026 was $0.0310. Our model-based fair value is $0.0377, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Medicine Corporation right now?
The price is below even our cautious bear case ($0.0324). The market is more pessimistic than our downside scenario. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of China Medicine Corporation
How large is the market capitalisation of China Medicine Corporation (CHME)?
The market capitalisation of China Medicine Corporation is $946K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of China Medicine Corporation (CHME)?
Earnings per share at China Medicine Corporation are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of China Medicine Corporation (CHME)?
The net margin of China Medicine Corporation is 9.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Medicine Corporation (CHME)?
The return on equity (ROE) of China Medicine Corporation is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Medicine Corporation (CHME)?
On an EBIT basis the return on assets of China Medicine Corporation is 27.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Medicine Corporation (CHME)?
The operating margin of China Medicine Corporation is 14.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Medicine Corporation (CHME)?
Revenue at China Medicine Corporation is growing −8.4% versus a year earlier (3y avg +39.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Medicine Corporation (CHME)?
Earnings per share at China Medicine Corporation are growing −73.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does China Medicine Corporation (CHME) generate?
The free cash flow of China Medicine Corporation is $13.3M (fiscal year 2009). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does China Medicine Corporation (CHME) carry?
The net debt of China Medicine Corporation is $9.0M (fiscal year 2009, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch China Medicine Corporation in the live analysis
One click puts China Medicine Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026